<DOC>
	<DOCNO>NCT00357617</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving celecoxib surgery may reduce amount normal tissue need remove . Collecting store sample tumor tissue , blood , urine patient head neck cancer study laboratory may help doctor learn cancer predict well patient respond treatment celecoxib . PURPOSE : This phase I/II trial study change tumor cell well celecoxib work treat patient head neck cancer remove surgery .</brief_summary>
	<brief_title>Celecoxib Treating Patients With Head Neck Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate change molecular marker angiogenesis treatment celecoxib tumor tissue patient resectable head neck squamous cell carcinoma . Secondary - Evaluate change molecular marker angiogenesis treatment celecoxib blood tissue patient . - Evaluate effect celecoxib indirect measure tumor perfusion , measure perfusion CT scan , patient . - Evaluate effect celecoxib apoptosis proliferation rate tumor cell endothelial cell patient . - Identify potential new marker activity cyclooxygenase-2 inhibitor identify new pathway potential interest perform gene expression profile tumor tissue exposure celecoxib . OUTLINE : This open-label , nonrandomized , uncontrolled study . Patients undergo panendoscopy tumor biopsy day 0 . Patients receive oral celecoxib twice daily begin day 1 continue least 14 days* . Patients undergo definitive surgery . NOTE : *Treatment continue day surgery . Tumor , blood , urine sample collect baseline periodically study . Tumor quantification perfusion CT scan perform baseline treatment celecoxib . Biological marker detect immunohistochemistry enzyme immunoassay . Blood vascular density , apoptosis , proliferation , endothelial cell : tumor ratio measure indirect hemagglutination . Gene expression measure microarray analysis . After surgery , patient follow 4 week periodically thereafter . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm high clinical suspicion squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx No carcinoma sinonasal nasopharynx Clinical stage T14 , N02 , M0 disease Tumor must consider resectable planned surgical excision No lymph node &gt; 6 cm ( N3 ) No distant metastasis PATIENT CHARACTERISTICS : Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Creatinine ≤ 1.5 time upper limit normal ( ULN ) Creatinine clearance ≥ 60 mL/min AST ALT ≤ 2.5 time ULN Bilirubin normal History prior malignancy allow evidence recurrence metastasis time screen No comorbidity preclude operability No known liver impairment Known recent gastric duodenal ulcer allow treat &gt; 6 week prior study enrollment No known hypersensitivity celecoxib No known allergic reaction sulfonamide , aspirin , NSAIDs No psychological , familial , sociological , geographical condition would interfere study compliance followup schedule Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : More 2 month since prior concurrent anticancer investigational drug More 2 week since prior concurrent nonsteroidal antiinflammatory drug ( NSAIDs ) corticosteroids No prior radiotherapy head neck region No concurrent radiotherapy No concurrent therapeutic anticoagulation No concurrent administration follow : Other cyclooxygenase2 inhibitor Aspirin Lowdose aspirin cardiovascular prophylaxis allow Aluminum magnesiumcontaining antacid ACE inhibitor Furosemide Known inhibitor P450 2C9 ( e.g. , fluconazole , fluoxetine , fluvoxamin , isoniazid , omeprazole ) Known inducer P450 2C9 ( e.g. , rifampin ) Lithium Acenocoumarol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>stage I squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
</DOC>